NEW YORK, July 22, 2020 /PRNewswire/ --
WeissLaw LLP is investigating possible breaches of
fiduciary duty and other violations of law by the Board of
Directors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the
"Company") (NASDAQ: REGN).
If you are a Regeneron shareholder and wish to
discuss this investigation or have any questions concerning this
notice or your rights or interests, visit our website:
http://www.weisslawllp.com/regeneron-pharmaceuticals-inc/
Or please contact:
Joshua Rubin,
Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
The investigation focuses on possible breaches of fiduciary duty
and violations of federal securities laws by the Regeneron Board of
Directors. Specifically, on June 24,
2020, the U.S. Attorney's Office filed a complaint against
the Company for alleged violations of the False Claims Act.
The complaint alleged that the Company engaged in a sophisticated
kickback scheme through which it funneled tens of millions of
dollars from a foundation with the goal of covering the co-pay
costs of Medicare patients of the Company's Eylea drug.
According to the U.S. Attorney's Office, the scheme undermined the
medical system and wasted taxpayers' monies by causing Medicare to
pay out nearly $2 billion for access
to the drug.
WeissLaw is investigating whether Regeneron's Board breached its
fiduciary duties to the Company and its shareholders by failing to
implement and maintain an effective system of internal controls
over its operations.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc-301098435.html
SOURCE WeissLaw LLP